{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:35:27Z","timestamp":1793216127088,"version":"4.5.0"},"reference-count":222,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacadv.2026.103279","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:04:26Z","timestamp":1790640266000},"page":"103279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2295-3106","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"S\u00e1ndor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-0784","authenticated-orcid":false,"given":"Zolt\u00e1n V.","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s G.","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia D.","family":"Drobni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-629X","authenticated-orcid":false,"given":"Jos\u00e9 J.","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Pozsonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.103279_bib1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib2","series-title":"Basics of hematopoietic stem cell transplant","first-page":"239","article-title":"Indications for autologous stem cell transplant","author":"Sharma","year":"2023"},{"key":"10.1016\/j.jacadv.2026.103279_bib3","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/imj.70148","article-title":"Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia","volume":"55","author":"McCaughan","year":"2025","journal-title":"Intern Med J"},{"key":"10.1016\/j.jacadv.2026.103279_bib4","doi-asserted-by":"crossref","first-page":"e40144","DOI":"10.1097\/MD.0000000000040144","article-title":"Hematopoietic stem cell transplantation therapy for refractory Crohn disease: a systematic review and meta-analysis","volume":"103","author":"Serrano-Fernandez","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacadv.2026.103279_bib5","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1007\/s10072-024-07308-y","article-title":"Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis","volume":"45","author":"Mariottini","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jacadv.2026.103279_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jacadv.2026.103279_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.mpmed.2021.02.011","article-title":"Principles of haemopoietic stem cell transplantation","volume":"49","author":"Dixon-Zegeye","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.jacadv.2026.103279_bib8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.12688\/f1000research.11233.1","article-title":"Recent advances in hematopoietic stem cell transplantation","volume":"6","author":"Norkin","year":"2017","journal-title":"F1000Res"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103279_bib9","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3324\/haematol.2022.281020","article-title":"Autologous stem cell transplantation in an older adult population","volume":"107","author":"Fedorov","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103279_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtct.2023.12.001","article-title":"International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update","volume":"30","author":"Rotz","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jacadv.2026.103279_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaccao.2024.06.004","article-title":"Cardiovascular disease after hematopoietic stem cell transplantation in adults","volume":"6","author":"Gent","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41409-023-01928-2","article-title":"Cardiovascular events among recipients of hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"58","author":"Aghel","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/jpm12111797","article-title":"Cardiovascular complications in hematopoietic stem cell transplanted patients","volume":"12","author":"Zhao","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11936-016-0447-9","article-title":"Cardiovascular complications of hematopoietic stem cell transplantation","volume":"18","author":"Blaes","year":"2016","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11239-020-02344-9","article-title":"Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation","volume":"51","author":"Rotz","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacadv.2026.103279_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/a-2284-5855","article-title":"Cardio-oncology: a new discipline in medicine and its relevance to hematology","volume":"44","author":"Spannbauer","year":"2024","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jacadv.2026.103279_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"Vasbinder","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib19","doi-asserted-by":"crossref","first-page":"e1113","DOI":"10.1161\/CIR.0000000000001220","article-title":"Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: from pretransplantation to survivorship: a scientific statement from the American Heart Association","volume":"149","author":"Hayek","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103279_bib20","first-page":"1","article-title":"Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival","volume":"9","author":"Auberle","year":"2023","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jacadv.2026.103279_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1556\/650.2026.33480","article-title":"Az autol\u00f3g \u0151ssejt-transzplant\u00e1ci\u00f3 kapcs\u00e1n fell\u00e9p\u0151 cardiovascularis sz\u00f6v\u0151dm\u00e9nyek: Aktualit\u00e1sok az onkokardiol\u00f3gia t\u00fckr\u00e9ben","volume":"167","author":"S\u00e1ndor","year":"2026","journal-title":"Orv Hetil"},{"key":"10.1016\/j.jacadv.2026.103279_bib22","series-title":"The EBMT handbook: hematopoietic cell transplantation and cellular therapies","first-page":"373","article-title":"Early complications of endothelial origin","author":"Carreras","year":"2024"},{"key":"10.1016\/j.jacadv.2026.103279_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41569-025-01126-1","article-title":"Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment","volume":"22","author":"Fabiani","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1406247","article-title":"An update of the molecular mechanisms underlying anthracycline-induced cardiotoxicity","volume":"15","author":"Xie","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacadv.2026.103279_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","article-title":"Cancer therapy-induced cardiotoxicity: mechanisms and mitigations","volume":"30","author":"Shil","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"Suppl 1","key":"10.1016\/j.jacadv.2026.103279_bib27","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1182\/blood-2024-210421","article-title":"Finding the sweet spot: melphalan dosing for autologous hematopoietic stem cell transplant for multiple myeloma in challenging environments","volume":"144","author":"Ghani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/10428194.2014.926346","article-title":"Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma","volume":"56","author":"Gul","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jacadv.2026.103279_bib29","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.transproceed.2014.09.053","article-title":"High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results","volume":"46","author":"Charlinski","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jacadv.2026.103279_bib30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bbmt.2019.01.032","article-title":"BEAM versus BUCYVP16 conditioning before autologous hematopoietic stem cell transplant in patients with Hodgkin lymphoma","volume":"25","author":"Singer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.transproceed.2022.12.001","article-title":"Comparative efficacy and safety of BEAM and TEAM conditioning regimens for autologous stem cell transplantation in lymphoma patients","volume":"55","author":"Deveci","year":"2023","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jacadv.2026.103279_bib32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12964-024-01974-3","article-title":"Inflammasomes: potential therapeutic targets in hematopoietic stem cell transplantation","volume":"22","author":"Luo","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jacadv.2026.103279_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s10557-024-07574-0","article-title":"A comprehensive overview on chemotherapy-induced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms","volume":"39","author":"Nagy","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacadv.2026.103279_bib34","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11886-024-02131-5","article-title":"Inflammation in chemotherapy-induced cardiotoxicity","volume":"26","author":"Hutchins","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacadv.2026.103279_bib35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.16621","article-title":"Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation","volume":"190","author":"Hildebrandt","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.bbmt.2010.02.008","article-title":"Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation","volume":"16","author":"Palomo","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2991\/chi.d.190317.001","article-title":"Endothelial dysfunction in hematopoietic cell transplantation","volume":"1","author":"Palomo","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jacadv.2026.103279_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101760","article-title":"Early cardiovascular events in recipients of allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Aghel","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaccao.2025.12.008","article-title":"Atrial fibrillation following autologous stem cell transplantation in multiple myeloma: incidence, predictors, and prognostic impact","volume":"8","author":"Bolaji","year":"2026","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib40","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.3324\/haematol.2021.279179","article-title":"Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma","volume":"106","author":"Srour","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib41","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/S0735-1097(24)04481-4","article-title":"Atrial arrhythmias and post-discharge outcomes following stem cell transplantation","volume":"83","author":"Zaghlol","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib42","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cncr.28444","article-title":"Cardiovascular disease in survivors of hematopoietic cell transplantation","volume":"120","author":"Armenian","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jacadv.2026.103279_bib43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clml.2019.12.027","article-title":"Cardiotoxicity in hematopoietic stem cell transplant: keeping the beat","volume":"20","author":"Baker","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacadv.2026.103279_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.34172\/jcvtr.33230","article-title":"Post-transplant cyclophosphamide-induced cardiotoxicity: a comprehensive review","volume":"16","author":"Alizadehasl","year":"2024","journal-title":"J Cardiovasc Thorac Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/23971983221145639","article-title":"Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis","volume":"8","author":"Penglase","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.jacadv.2026.103279_bib46","article-title":"Cardiovascular diseases in patients after hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"71","author":"Alizadehasl","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib47","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00277-016-2673-3","article-title":"Venous thromboembolism following hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"95","author":"Zahid","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bmt.2015.308","article-title":"Venous thromboembolism in hematopoietic stem cell transplant recipients","volume":"51","author":"Chaturvedi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2023.04.019","article-title":"Venous thromboembolism in hematopoietic stem cell transplantation: a narrative review","volume":"226","author":"Chiu","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib50","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jacadv.2026.103279_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70165","article-title":"Long-term clinical outcomes after autologous hematopoietic stem cell transplantation in 49 individuals living with HIV and affected by high-risk or relapsed lymphoma: a European experience of continued relevance for people living with HIV","volume":"97","author":"Zanet","year":"2025","journal-title":"J Med Virol"},{"key":"10.1016\/j.jacadv.2026.103279_bib53","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.1016\/j.clml.2020.03.006","article-title":"Long-term Hodgkin lymphoma survivors: a glimpse of what happens 10 years after treatment","volume":"20","author":"Laddaga","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacadv.2026.103279_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/cancers14010061","article-title":"Late cardiological sequelae and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi","volume":"14","author":"Oliva","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jacadv.2026.103279_bib55","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11864-024-01240-1","article-title":"Cardiovascular considerations in patients undergoing hematopoietic cell transplantation","volume":"25","author":"Hundal","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib56","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib58","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2024.49","article-title":"Cardio-oncology: emerging concepts in cardiovascular sequelae of cancer therapies, translational research and reverse cardio-oncology","volume":"20","author":"Camilli","year":"2025","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaccao.2025.07.001","article-title":"Cancer and cardiovascular disease: shared risk factors, mechanisms, and clinical implications: JACC: cardiooncology state-of-the-art review","volume":"7","author":"Alhuneafat","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib60","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/eurheartj\/ehae105","article-title":"Heart failure pharmacotherapy and cancer: pathways and pre-clinical\/clinical evidence","volume":"45","author":"Sayour","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102389","article-title":"Evolving perspectives in reverse cardio-oncology: a review of current status, pathophysiological insights, and future directives","volume":"49","author":"Imran","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib62","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ejhf.2071","article-title":"Advanced cancer is also a heart failure syndrome: a hypothesis","volume":"23","author":"Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103279_bib63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103279_bib64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib65","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaccao.2025.05.016","article-title":"Cancer development in atherosclerotic cardiovascular disease","volume":"7","author":"Dalman","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib66","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaccao.2024.09.009","article-title":"Cancer prevention and early detection in patients with cardiovascular disease","volume":"6","author":"Ameri","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib67","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2023022222","article-title":"Causes and consequences of clonal hematopoiesis","volume":"142","author":"Weeks","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib68","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib69","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jacadv.2026.103279_bib70","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease","volume":"81","author":"Gumuser","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib71","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1038\/s41591-024-03213-1","article-title":"Unidirectional association of clonal hematopoiesis with atherosclerosis development","volume":"30","author":"D\u00edez-D\u00edez","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s44161-022-00206-6","article-title":"TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease","volume":"2","author":"Zekavat","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib73","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1161\/CIR.0000000000001404","article-title":"Clonal hematopoiesis and its cardiovascular implications: a scientific statement from the American Heart Association","volume":"153","author":"Rhee","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103279_bib74","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacadv.2026.103279_bib75","doi-asserted-by":"crossref","first-page":"1419323","DOI":"10.3389\/frhem.2024.1419323","article-title":"Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets","volume":"3","author":"Taborda","year":"2024","journal-title":"Front Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib76","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/bloodadvances.2024013228","article-title":"Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis","volume":"8","author":"Singh","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib77","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib78","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jacadv.2026.103279_bib79","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","article-title":"Variant allele frequency: a decision-making tool in precision oncology?","volume":"9","author":"Boscolo Bielo","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jacadv.2026.103279_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13039-025-00718-3","article-title":"What the VAF? A guide to the interpretation of variant allele fraction, percent mosaicism, and copy number in cancer","volume":"18","author":"Smith","year":"2025","journal-title":"Mol Cytogenet"},{"key":"10.1016\/j.jacadv.2026.103279_bib81","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/hematology.2021000272","article-title":"When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?","volume":"2021","author":"Osman","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jacadv.2026.103279_bib83","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib84","doi-asserted-by":"crossref","first-page":"e180065","DOI":"10.1172\/JCI180065","article-title":"Clonal hematopoiesis and hematological malignancy","volume":"134","author":"Dunn","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacadv.2026.103279_bib85","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacadv.2026.103279_bib87","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacadv.2026.103279_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib89","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib90","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3324\/haematol.2021.280021","article-title":"Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity","volume":"107","author":"Feldkamp","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106787","article-title":"Clonal hematopoiesis: molecular and clinical implications","volume":"113","author":"Kusne","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib92","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s41409-024-02403-2","article-title":"Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis","volume":"59","author":"Xie","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib93","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.2025028417","article-title":"Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women","volume":"146","author":"Pershad","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib94","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3390\/cancers16152634","article-title":"Decoding clonal hematopoiesis: emerging themes and novel mechanistic insights","volume":"16","author":"Pendse","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jacadv.2026.103279_bib95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-genom-120722-100409","article-title":"Clinical and therapeutic implications of clonal hematopoiesis","volume":"25","author":"Petrone","year":"2024","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jacadv.2026.103279_bib96","doi-asserted-by":"crossref","first-page":"e180068","DOI":"10.1172\/JCI180068","article-title":"CHIP: a clonal odyssey of the bone marrow niche","volume":"134","author":"Schleicher","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacadv.2026.103279_bib97","first-page":"457","article-title":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis","volume":"111","author":"Wong","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib98","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-025-01148-9","article-title":"Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target","volume":"22","author":"Schuermans","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib99","doi-asserted-by":"crossref","first-page":"1303785","DOI":"10.3389\/fonc.2023.1303785","article-title":"Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential","volume":"13","author":"Cacic","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib100","doi-asserted-by":"crossref","first-page":"1796328","DOI":"10.3389\/fcvm.2026.1796328","article-title":"Clonal hematopoiesis of indeterminate potential and cardiovascular disease: mechanistic insights, clinical implications, and the dawn of precision cardio-hematology","volume":"13","author":"Wu","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib101","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/eurheartj\/ehaf602","article-title":"Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease","volume":"47","author":"von Scheidt","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2026.111267","article-title":"TET2 in epigenetic control of immune cells: implications for inflammatory responses and age-related pathologies","volume":"302","author":"Obrebski","year":"2026","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2026.103279_bib103","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jacadv.2026.103279_bib104","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/CIRCULATIONAHA.123.065344","article-title":"BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in TET2 clonal hematopoiesis","volume":"148","author":"Yalcinkaya","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103279_bib105","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood.2022016835","article-title":"Aging drives Tet2+\/\u2212 clonal hematopoiesis via IL-1 signaling","volume":"141","author":"Caiado","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib106","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1038\/s41467-023-43697-y","article-title":"Clonal hematopoiesis-related TET2 loss-of-function impedes IL-1\u03b2-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells","volume":"14","author":"McClatchy","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacadv.2026.103279_bib107","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood-2024-206384","article-title":"Hematopoietic stem cell aging promotes expansion of Tet2 mutant clones by cell-intrinsic mechanisms","volume":"144","author":"De Dominici","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib108","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/bloodadvances.2023011833","article-title":"Chronic TNF in the aging microenvironment exacerbates Tet2 loss-of-function myeloid expansion","volume":"8","author":"Quin","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s44161-021-00015-3","article-title":"Clonal hematopoiesis in cardiovascular disease and therapeutic implications","volume":"1","author":"Tall","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12185-025-04038-5","article-title":"ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights","volume":"122","author":"Sato","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib111","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s44161-024-00579-w","article-title":"Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity","volume":"3","author":"Sato","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000688","article-title":"Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease","volume":"29","author":"Cobo","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib113","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/eurheartj\/ehad670","article-title":"Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias","volume":"45","author":"Schuermans","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib114","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/bloodadvances.2025018031","article-title":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias","volume":"10","author":"Badar","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib115","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1182\/blood-2024-202688","article-title":"PPM1D somatic mutations in myeloid neoplasms: clinical profile, clonal characteristics, and impact of concurrent somatic TP53 mutations","volume":"144","author":"Badar","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib116","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00018-020-03694-6","article-title":"The regulatory roles of p53 in cardiovascular health and disease","volume":"78","author":"Men","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jacadv.2026.103279_bib117","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1182\/blood-2025-5168","article-title":"TP53 and PPM1D mutations in AML: distinct frequencies, shared pathway, and adverse prognostic trends","volume":"146","author":"Abuamsha","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib118","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jacadv.2026.103279_bib119","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-023-01382-9","article-title":"Clonal hematopoiesis of indeterminate potential: current understanding and future directions","volume":"25","author":"Singh","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jacadv.2026.103279_bib120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s43141-021-00205-3","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases: an updated systematic review","volume":"19","author":"Senguttuvan","year":"2021","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.jacadv.2026.103279_bib121","first-page":"1135","article-title":"Molecular pathways in clonal hematopoiesis: from the acquisition of somatic mutations to transformation into hematologic neoplasm","volume":"12","author":"Gaulin","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jacadv.2026.103279_bib122","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacadv.2026.103279_bib123","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jacadv.2026.103279_bib124","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41588-024-01755-1","article-title":"Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis","volume":"56","author":"Bernstein","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacadv.2026.103279_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70169","article-title":"CHIC: a machine learning framework for inferring the presence of high-risk clonal hematopoiesis using complete blood count data from 431,531 UK Biobank participants","volume":"9","author":"Dunn","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.jacadv.2026.103279_bib126","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41580-025-00936-y","article-title":"Inflammageing and clonal haematopoiesis interplay and their impact on human disease","volume":"27","author":"Hajishengallis","year":"2026","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jacadv.2026.103279_bib127","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib128","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.3324\/haematol.2024.285392","article-title":"Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action","volume":"109","author":"Gillis","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/j.seminhematol.2024.01.011","article-title":"Clonal hematopoiesis in the setting of hematopoietic cell transplantation","volume":"61","author":"Gibson","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib130","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.3324\/haematol.2023.282992","article-title":"Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib131","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41375-024-02258-y","article-title":"Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders","volume":"38","author":"Awada","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jacadv.2026.103279_bib132","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.23.02547","article-title":"Clonal hematopoiesis and therapy-related myeloid neoplasms after autologous transplant for Hodgkin lymphoma","volume":"42","author":"Yan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib133","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCRESAHA.117.312115","article-title":"Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease","volume":"122","author":"Fuster","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib134","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/cells13080657","article-title":"Single-cell DNA sequencing reveals an evolutionary pattern of CHIP in transplant-eligible multiple myeloma patients","volume":"13","author":"Borsi","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jacadv.2026.103279_bib135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41375-025-02823-z","article-title":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation","volume":"40","author":"Stein","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.jacadv.2026.103279_bib136","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.celrep.2019.04.064","article-title":"Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation","volume":"27","author":"Ortmann","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jacadv.2026.103279_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100744","article-title":"The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation","volume":"46","author":"Nawas","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jacadv.2026.103279_bib138","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","article-title":"Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib139","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacadv.2026.103279_bib140","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood-2017-09-805879","article-title":"Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT","volume":"131","author":"Berger","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib141","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/bloodadvances.2019001157","article-title":"Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation","volume":"4","author":"Soerensen","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib142","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41409-022-01567-z","article-title":"Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation","volume":"57","author":"Soerensen","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib143","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-24475-w","article-title":"Prospective characterization of clonal hematopoiesis and its clinical associations in elderly patients","volume":"15","author":"Moyen","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2026.103279_bib144","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamacardio.2023.4105","article-title":"Clonal hematopoiesis and cardiovascular disease in patients with multiple myeloma undergoing hematopoietic cell transplant","volume":"9","author":"Rhee","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib146","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","article-title":"National Institutes of Health Hematopoietic cell transplantation late effects initiative: the cardiovascular disease and Associated Risk Factors Working Group report","volume":"23","author":"Armenian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib147","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/bloodadvances.2022007497","article-title":"Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study","volume":"7","author":"Hazenberg","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib148","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib149","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033599","article-title":"Cardiovascular risk stratification of patients undergoing hematopoietic stem cell transplantation: the CARE-BMT risk score","volume":"13","author":"Vasbinder","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2026.103279_bib150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaccao.2022.12.001","article-title":"Cardio-oncology guidelines and strength of the evidence","volume":"5","author":"Zheng","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib151","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.3390\/cancers16223808","article-title":"Evaluation of subclinical cancer therapy-related cardiac dysfunction in patients undergoing hematopoietic stem cell transplantation: an echocardiography study","volume":"16","author":"Vaitiekiene","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jacadv.2026.103279_bib152","article-title":"Subclinical myocardial changes after hematopoietic stem cell transplantation: limited predictive value of early biomarkers and strain imaging","author":"Oliver","year":"2026","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jacadv.2026.103279_bib153","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaccao.2021.09.012","article-title":"How to perform hematopoietic stem cell transplantation","volume":"3","author":"Majhail","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib154","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jaccao.2025.07.011","article-title":"Cardiovascular and oncologic considerations in adult Hodgkin lymphoma: JACC: cardiooncology state-of-the-art review","volume":"7","author":"Raman","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12032-018-1221-5","article-title":"Evaluation of the impact of treatment with hematopoietic stem cell transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies","volume":"35","author":"Por\u0119ba","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib156","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12534","article-title":"The analysis of the parameters of 24-hour ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation","volume":"23","author":"Por\u0119ba","year":"2018","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib157","first-page":"89","article-title":"A kardiotoxicit\u00e1s defin\u00edci\u00f3j\u00e1nak evol\u00faci\u00f3ja \u00e9s \u00fajra\u00e9rtelmez\u00e9se","volume":"53","author":"Czuriga","year":"2023","journal-title":"Cardiol Hung"},{"key":"10.1016\/j.jacadv.2026.103279_bib158","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaccao.2020.06.011","article-title":"Left ventricular systolic function in long-term survivors of allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Massey","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib159","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1536\/ihj.20-434","article-title":"Serial changes in cardiac strain and contractility after hematopoietic stem cell transplantation in patients with hematologic malignancies","volume":"62","author":"Oka","year":"2021","journal-title":"Int Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib160","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2009.06.001","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction","volume":"15","author":"Qazilbash","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib161","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.bmt.1702466","article-title":"Cardiac systolic function before and after hematopoietic stem cell transplantation","volume":"26","author":"Lehmann","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacadv.2026.103279_bib162","doi-asserted-by":"crossref","first-page":"465","DOI":"10.21320\/2500-2139-2016-9-4-465-473","article-title":"Biochemical markers of cardiotoxicity of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with malignant lymphoproliferative disorders","volume":"9","author":"Sarzhevskii","year":"2016","journal-title":"Clin Oncohematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib163","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.clml.2022.12.010","article-title":"High-dose chemotherapy impairs cardiac autonomic control of hospitalized cancer patients undergoing autologous hematopoietic stem cell transplantation","volume":"23","author":"de Almeida","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacadv.2026.103279_bib164","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-9966-31-13","article-title":"Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation","volume":"31","author":"Roziakova","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaccao.2022.11.013","article-title":"The ESC 2022 cardio-oncology guidelines and the road ahead in cardio-oncology","volume":"5","author":"Cheng","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib166","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaccao.2022.10.008","article-title":"ESC cardio-oncology guidelines","volume":"5","author":"Witteles","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103279_bib167","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51927","article-title":"Clonal hematopoiesis risk score and all-cause and cardiovascular mortality in older adults","volume":"7","author":"Saadatagah","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacadv.2026.103279_bib168","article-title":"Clonal hematopoiesis risk score (CHRS) evaluation as a prognostic marker for death in cardio-oncology cohort","volume":"4","author":"Singh","year":"2025","journal-title":"JACC: Adv"},{"key":"10.1016\/j.jacadv.2026.103279_bib169","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDe2300053","article-title":"How great is the threat of clonal hematopoiesis? Let this new risk score be your guide","volume":"2","author":"Xie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacadv.2026.103279_bib170","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacadv.2026.103279_bib171","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.3390\/jcm14248681","article-title":"How to read a next-generation sequencing report for AML and MDS? What hematologists need to know","volume":"14","author":"Perrone","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib172","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318300","article-title":"Error-corrected ultradeep next-generation sequencing for detection of clonal haematopoiesis and haematological neoplasms: sensitivity, specificity, and accuracy","volume":"20","author":"Tursky","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2026.103279_bib174","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s44325-026-00127-4","article-title":"Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future","volume":"3","author":"Morley","year":"2026","journal-title":"NPJ Cardiovasc Health"},{"key":"10.1016\/j.jacadv.2026.103279_bib175","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00277-025-06244-x","article-title":"Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms, and inflammation","volume":"104","author":"Tan","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib176","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ejh.13322","article-title":"Arrhythmias in hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"103","author":"Chiengthong","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib177","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11239-023-02902-x","article-title":"Characterization of direct oral anticoagulants use in adult hematopoietic stem cell transplant recipients","volume":"57","author":"Yang","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacadv.2026.103279_bib178","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s11239-021-02393-8","article-title":"Anticoagulation in patients with atrial fibrillation, thrombocytopenia, and hematological malignancy","volume":"52","author":"Livneh","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacadv.2026.103279_bib179","doi-asserted-by":"crossref","first-page":"1740067","DOI":"10.3389\/fimmu.2026.1740067","article-title":"Comprehensive management of hematopoietic stem cell transplantation complications: from infection prevention to immune microenvironment reconstruction","volume":"17","author":"Song","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacadv.2026.103279_bib180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13287-024-04126-z","article-title":"Hematopoietic stem cells: understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation","volume":"16","author":"Aljagthmi","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jacadv.2026.103279_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101001","article-title":"CHIPing away the progression potential of CHIP: a new reality in the making","volume":"58","author":"Xie","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jacadv.2026.103279_bib182","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib183","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.jacc.2025.08.025","article-title":"Colchicine and longitudinal dynamics of clonal hematopoiesis","volume":"86","author":"Mohammadnia","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib184","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1161\/CIRCULATIONAHA.125.077665","article-title":"Low-dose colchicine attenuates clonal hematopoiesis in COLCOT","volume":"153","author":"Tardif","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103279_bib185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamacardio.2024.3773","article-title":"Clonal hematopoiesis of indeterminate potential","volume":"10","author":"Libby","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib186","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib187","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.70205","article-title":"Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2026 update on clinical associations and management recommendations","volume":"101","author":"Mangaonkar","year":"2026","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib188","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11886-022-01724-2","article-title":"Somatic mutations and clonal hematopoiesis as drivers of age-related cardiovascular risk","volume":"24","author":"Haring","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacadv.2026.103279_bib189","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib190","first-page":"13","article-title":"Clonal hematopoiesis of indeterminate potential and cardiovascular health","volume":"43","author":"Raddatz","year":"2025","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacadv.2026.103279_bib191","article-title":"Analysis of the effects of statin therapy on clonal dynamics in clonal haematopoiesis of indeterminate potential: insights from the English Longitudinal Study of Ageing","author":"Musson","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.jacadv.2026.103279_bib192","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamacardio.2025.3756","article-title":"Clonal hematopoiesis and cardiovascular disease and bleeding risk and the effectiveness of aspirin","volume":"10","author":"McQuilten","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101323","article-title":"Target practice: opportunities for therapeutic intervention in CHIP and CCUS","volume":"74","author":"Mohammad","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.jacadv.2026.103279_bib194","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/hemato6020010","article-title":"Clonal hematopoiesis, a risk condition for developing myeloid neoplasia","volume":"6","author":"Testa","year":"2025","journal-title":"Hemato"},{"key":"10.1016\/j.jacadv.2026.103279_bib195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10557-020-06943-9","article-title":"Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-\/- Mice","volume":"34","author":"Tang","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacadv.2026.103279_bib196","first-page":"1566","article-title":"Novel and emerging therapeutic strategies for clonal hematopoiesis","volume":"111","author":"Hosseini","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib197","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.seminhematol.2024.01.013","article-title":"TET2 mutation as prototypic clonal hematopoiesis lesion","volume":"61","author":"Guarnera","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib198","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood.2024024962","article-title":"High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib199","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2024-210278","article-title":"Vitamin A directly enhances TET2 activity and suppresses clonal hematopoiesis","volume":"144","author":"Brabson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2026.103279_bib200","article-title":"Hematopoietic stem cell aging promotes TET2 clonal hematopoiesis","author":"De Dominici","year":"2026","journal-title":"Res Sq"},{"key":"10.1016\/j.jacadv.2026.103279_bib201","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib202","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1093\/eurheartj\/ehae546","article-title":"Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis","volume":"45","author":"Zuriaga","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103279_bib203","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103279_bib204","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41586-025-08980-6","article-title":"Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis","volume":"642","author":"Gozdecka","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jacadv.2026.103279_bib205","article-title":"Metformin reduces the clonal fitness of Dnmt3a(R878H) hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state","author":"Hosseini","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.jacadv.2026.103279_bib206","article-title":"Using metformin to stall clonal hematopoiesis","author":"O'Leary","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2026.103279_bib207","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s43556-025-00311-5","article-title":"Metformin modulates mitochondrial metabolism and epigenetic dysregulation in DNMT3A-mutated clones","volume":"6","author":"Hu","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.jacadv.2026.103279_bib208","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1038\/s41467-025-57238-2","article-title":"Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis","volume":"16","author":"Young","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacadv.2026.103279_bib209","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1078-0432.CCR-25-3606","article-title":"Metformin does not significantly alter longitudinal dynamics of clonal hematopoiesis","volume":"32","author":"Pareek","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacadv.2026.103279_bib210","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-026-02526-w","article-title":"CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis","volume":"58","author":"Chan","year":"2026","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacadv.2026.103279_bib211","first-page":"1536","article-title":"Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies","volume":"111","author":"Beeler","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.jacadv.2026.103279_bib212","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180069","article-title":"Distinct landscape and clinical implications of therapy-related clonal hematopoiesis","volume":"134","author":"Takahashi","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacadv.2026.103279_bib213","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1186\/s12885-024-12782-w","article-title":"CDK4\/6 inhibitors plus endocrine therapy vs placebo plus endocrine therapy for HR+\/HER2\u2212 advanced breast cancer: a phase III randomized controlled trials-based meta-analysis","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jacadv.2026.103279_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1673284","article-title":"Toxicity profiles of cyclin-dependent kinase 4\/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib215","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/HER2\u2212 breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Pu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacadv.2026.103279_bib216","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3390\/cancers16162869","article-title":"Profiling the cardiovascular toxicities of CDK4\/6 inhibitors: a real-world pharmacovigilance study","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jacadv.2026.103279_bib217","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e15074","article-title":"CDK4\/6 inhibitors and cardiovascular toxicity: real-world evidence","volume":"41","author":"Fiste","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103069","article-title":"Risk of QTc prolongation and major cardiovascular adverse events associated with CDK4\/6 inhibitors in hormone receptor-positive HER2-negative breast cancer: a systematic review and meta-analysis","volume":"142","author":"Hoo","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jacadv.2026.103279_bib219","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae078","article-title":"QTc prolongation across CDK4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Murad","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jacadv.2026.103279_bib220","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/ajh.26726","article-title":"Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma","volume":"97","author":"Lackraj","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacadv.2026.103279_bib221","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.18.00331","article-title":"Managing clonal hematopoiesis in patients with solid tumors","volume":"37","author":"Bolton","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacadv.2026.103279_bib222","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.mayocp.2018.04.002","article-title":"Clinical implications of clonal hematopoiesis","volume":"93","author":"Steensma","year":"2018","journal-title":"Mayo Clin Proc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:25:58Z","timestamp":1793215558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26007003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":222,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2772963X26007003"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103279","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103279"}}